CN114340600A - 包含靛蓝和/或靛蓝衍生物的组合物及其使用方法 - Google Patents

包含靛蓝和/或靛蓝衍生物的组合物及其使用方法 Download PDF

Info

Publication number
CN114340600A
CN114340600A CN202080042143.2A CN202080042143A CN114340600A CN 114340600 A CN114340600 A CN 114340600A CN 202080042143 A CN202080042143 A CN 202080042143A CN 114340600 A CN114340600 A CN 114340600A
Authority
CN
China
Prior art keywords
indirubin
dosage form
indigo
dispersion
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042143.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·戴维森
J·塞基
J·安德雷森
M·D·法韦罗
M·B·格林尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azola Therapy Co ltd
Original Assignee
Azola Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azola Therapy Co ltd filed Critical Azola Therapy Co ltd
Publication of CN114340600A publication Critical patent/CN114340600A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080042143.2A 2019-05-03 2020-05-01 包含靛蓝和/或靛蓝衍生物的组合物及其使用方法 Pending CN114340600A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843184P 2019-05-03 2019-05-03
US62/843,184 2019-05-03
PCT/US2020/031174 WO2020227151A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Publications (1)

Publication Number Publication Date
CN114340600A true CN114340600A (zh) 2022-04-12

Family

ID=70775588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042143.2A Pending CN114340600A (zh) 2019-05-03 2020-05-01 包含靛蓝和/或靛蓝衍生物的组合物及其使用方法

Country Status (10)

Country Link
US (3) US20200345645A1 (enExample)
EP (1) EP3962458A1 (enExample)
JP (1) JP2022531012A (enExample)
KR (1) KR20220044435A (enExample)
CN (1) CN114340600A (enExample)
AU (1) AU2020269379A1 (enExample)
CA (1) CA3136081A1 (enExample)
MX (1) MX2021013386A (enExample)
TW (1) TW202106296A (enExample)
WO (1) WO2020227151A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
KR20240152820A (ko) 2021-11-30 2024-10-22 엔도퀘스트 로보틱스 인코포레이티드 로봇 제어 의료 기기용 힘 전달 시스템
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases
JP2025532421A (ja) * 2022-10-10 2025-09-29 上海澤徳曼医薬科技有限公司 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用
WO2025008784A1 (en) * 2023-07-04 2025-01-09 Glenmark Life Sciences Limited Solid dispersions of tapinarof and a process for the preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
EP2863897B1 (en) * 2012-06-21 2019-06-19 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物
BR112017021190B1 (pt) 2015-04-09 2021-12-21 Galderma Sa. Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis
BR112018071370A2 (pt) * 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de mesalazina
JP7325753B2 (ja) * 2018-01-18 2023-08-15 慶應義塾 潰瘍性大腸炎治療カプセル剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Also Published As

Publication number Publication date
TW202106296A (zh) 2021-02-16
US20200345645A1 (en) 2020-11-05
CA3136081A1 (en) 2020-11-12
US20220249382A1 (en) 2022-08-11
EP3962458A1 (en) 2022-03-09
AU2020269379A1 (en) 2021-12-02
KR20220044435A (ko) 2022-04-08
MX2021013386A (es) 2022-03-22
WO2020227151A1 (en) 2020-11-12
US20250255820A1 (en) 2025-08-14
JP2022531012A (ja) 2022-07-05

Similar Documents

Publication Publication Date Title
CN114340600A (zh) 包含靛蓝和/或靛蓝衍生物的组合物及其使用方法
BRPI0608853B1 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
NO173317B (no) Fremgangsmaate for fremstilling av et fast farmasoeytisk preparat med forsinket frigjoering
EP2349289A1 (en) Pharmaceutical compositions containing diacerein
EP3923914B1 (en) Afabicin formulation, method for making the same
CN101431992A (zh) 包含尼美舒利的新型低剂量药物组合物及其制备和用途
MX2008000967A (es) Nueva composicion farmaceutica de forma de dosis de liberacion modificada que comprende inhibidor de enzima ciclooxigenasa.
WO2022138717A1 (ja) 経口固形製剤
US20200345691A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
CN100488515C (zh) 一种地红霉素肠溶微丸及制备方法
WO2018111991A1 (en) Pharmaceutical composition containing celecoxib
US20210369624A1 (en) Solid oral dosage form having excellent dissolution properties
JP3947244B2 (ja) 消化性潰瘍治療用製剤
EP4054613A1 (en) Gut-protective compositions comprising boswellic acid
JPH04368330A (ja) ペミロラストカリウムの徐放性製剤
KR0184350B1 (ko) 오메프라졸 구강점막 부착 정제 조성물
HK40063531A (en) Afabicin formulation, method for making the same
HK40063531B (en) Afabicin formulation, method for making the same
JP2024004706A (ja) 医薬組成物及び医薬製剤
TW202510861A (zh) 泮托拉唑藥物組合物、其製備方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination